{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:48:00Z","timestamp":1776091680042,"version":"3.50.1"},"reference-count":45,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,10,15]]},"DOI":"10.2169\/internalmedicine.0739-22","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T22:31:24Z","timestamp":1697322684000},"page":"3013-3020","source":"Crossref","is-referenced-by-count":2,"title":["Anti-Kv1.4 Antibody-positive Nivolumab-induced Myasthenia Gravis and Myositis Presenting with Bilateral Ptosis and Demonstrating Different Pathophysiologies"],"prefix":"10.2169","volume":"62","author":[{"given":"Yuki","family":"Kitazaki","sequence":"first","affiliation":[{"name":"Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Yamamura","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan"},{"name":"Department of Community Medicine, Faculty of Medical Science, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Usui","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asako","family":"Ueno","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan"},{"name":"Department of Neurology, Fukui-ken Saiseikai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Sanada","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohito","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Endo","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichi","family":"Enomoto","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamichi","family":"Ikawa","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan"},{"name":"Department of Advanced Medicine for Community Healthcare, Faculty of Medical Sciences, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunari","family":"Nakamoto","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadanori","family":"Hamano","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan"},{"name":"Department of Aging and Dementia, Faculty of Medical Sciences, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012.","DOI":"10.1038\/nrc3239"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203: 883-895, 2006.","DOI":"10.1084\/jem.20051776"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 33: 1430-1437, 2015.","DOI":"10.1200\/JCO.2014.59.0703"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369: 122-133, 2013.","DOI":"10.1056\/NEJMoa1302369"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 26: 1824-1829, 2015.","DOI":"10.1093\/annonc\/mdv182"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27: 559-574, 2016.","DOI":"10.1093\/annonc\/mdv623"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 28: 2377-2385, 2017.","DOI":"10.1093\/annonc\/mdx286"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Huang YT, Chen YP, Lin WC, Su WC, Sun YT. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol 11: 634, 2020.","DOI":"10.3389\/fneur.2020.00634"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60: 210-225, 2016.","DOI":"10.1016\/j.ejca.2016.02.024"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Johansen A, Christensen SJ, Scheie D, H\u00f8jgaard JLS, Kondziella D. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review. Neurology 92: 663-674, 2019.","DOI":"10.1212\/WNL.0000000000007235"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89: 1127-1134, 2017.","DOI":"10.1212\/WNL.0000000000004359"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391: 933, 2018.","DOI":"10.1016\/S0140-6736(18)30533-6"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 82: 128-136, 2017.","DOI":"10.1016\/j.ejca.2017.05.041"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Takamatsu K, Nakane S, Suzuki S, et al. Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia. Ann Clin Transl Neurol 5: 1421-1427, 2018.","DOI":"10.1002\/acn3.654"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. van der Geld HW, Strauss AJ. Myasthenia gravis. Immunological relationship between striated muscle and thymus. Lancet 1: 57-60, 1966.","DOI":"10.1016\/S0140-6736(66)92356-7"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Suzuki S, Utsugisawa K, Yoshikawa H, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 66: 1334-1338, 2009.","DOI":"10.1001\/archneurol.2009.229"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Suzuki S, Utsugisawa K, Nagane Y, Suzuki N. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis 2011: 740583, 2011.","DOI":"10.4061\/2011\/740583"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kufukihara K, Watanabe Y, Inagaki T, et al. Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and\/or myocarditis. Sci Rep 9: 5284, 2019.","DOI":"10.1038\/s41598-019-41730-z"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 64: 1968-1970, 2005.","DOI":"10.1212\/01.WNL.0000163988.28892.79"},{"key":"20","unstructured":"20. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al.; Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Myasthenia gravis: recommendations for clinical research standards. Ann Thorac Surg 70: 327-334, 2000."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Komatsu M, Hirai M, Kobayashi K, et al. A rare case of nivolumab-related myasthenia gravis and myocarditis in a patient with metastatic gastric cancer. BMC Gastroenterol 21: 333, 2021.","DOI":"10.1186\/s12876-021-01904-4"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Sugiyama Y, Esa Y, Watanabe A, Kobayashi J, Suzuki S, Takahashi D. [Immune checkpoint inhibitor-induced anti-striational antibodies in myasthenia gravis and myositis: a case report]. Rinsho Shinkeigaku 61: 630-634, 2021 (in Japanese).","DOI":"10.5692\/clinicalneurol.cn-001604"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Isami A, Uchiyama A, Shimaoka Y, Suzuki S, Kawachi I, Fujita N. [A case of anti-titin antibody positive nivolumab-related necrotizing myopathy with myasthenia gravis]. Rinsho Shinkeigaku 59: 431-435, 2019 (in Japanese).","DOI":"10.5692\/clinicalneurol.cn-001270"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sugiyama A, Onishi Y, Ito K, et al. Marked respiratory failure in an ambulant patient with immune-mediated necrotizing myopathy and anti-Kv1.4 and anti-titin antibodies. Intern Med 60: 2671-2675, 2021.","DOI":"10.2169\/internalmedicine.6834-20"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7: 319, 2019.","DOI":"10.1186\/s40425-019-0774-y"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Mittal MK, Barohn RJ, Pasnoor M, et al. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response. J Clin Neuromuscul Dis 13: 46-52, 2011.","DOI":"10.1097\/CND.0b013e31821c5634"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Chatzistefanou KI, Kouris T, Iliakis E, et al. The ice pack test in the differential diagnosis of myasthenic diplopia. Ophthalmology 116: 2236-2243, 2009.","DOI":"10.1016\/j.ophtha.2009.04.039"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 37: 141-149, 2008.","DOI":"10.1002\/mus.20950"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Seki M, Kitano S, Suzuki S. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies. Cancer Immunol Immunother 71: 769-775, 2022.","DOI":"10.1007\/s00262-021-03053-9"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. Muscle Nerve 37: 141-149, 2008.","DOI":"10.1002\/mus.20950"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Seki M, Uruha A, Ohnuki Y, et al. Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun 100: 105-113, 2019.","DOI":"10.1016\/j.jaut.2019.03.005"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Romi F, Skeie GO, Gilhus NE, et al. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 62: 442-446, 2005.","DOI":"10.1001\/archneur.62.3.442"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Helgeland G, Petzold A, Hoff JM, et al. Anti-heat shock protein 70 antibody levels are increased in myasthenia gravis and Guillain-Barr\u00e9 syndrome. J Neuroimmunol 225: 180-183, 2010.","DOI":"10.1016\/j.jneuroim.2010.04.024"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Suzuki S, Utsugisawa K, Nagane Y, et al. Classification of myasthenia gravis based on autoantibody status. Arch Neurol 64: 1121-1124, 2007.","DOI":"10.1001\/archneur.64.8.1121"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Suzuki S, Nagane Y, Uzawa A, et al. Anti-striational antibodies: expanding their clinical significance. Clin Exp Neuroimmunol 11: 218-224, 2020.","DOI":"10.1111\/cen3.12611"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Romi F, Suzuki S, Suzuki N, et al. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J Neurol 259: 1312-1316, 2012.","DOI":"10.1007\/s00415-011-6344-y"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med 4: 272, 2016.","DOI":"10.21037\/atm.2016.07.10"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 45: 7-18, 2016.","DOI":"10.1016\/j.ctrv.2016.02.003"},{"key":"39","unstructured":"39. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 4: 560-575, 2015."},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Weber JS, Postow M, Lao CD, Schadendorf D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist 21: 1230-1240, 2016.","DOI":"10.1634\/theoncologist.2016-0055"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Aldea M, Orillard E, Mansi L, et al. How to manage patients with corticosteroids in oncology in the era of immunotherapy? Eur J Cancer 141: 239-251, 2020.","DOI":"10.1016\/j.ejca.2020.09.032"},{"key":"42","unstructured":"42. Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1. 2019. J Natl Compr Canc Netw 17: 255-289, 2019."},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Ziogas DC, Mandellos D, Theocharopoulos C, et al. Neuromuscular complications of targeted anticancer agents: can tyrosine kinase inhibitors induce myasthenia gravis? Getting answers from a case report up to a systematic review. Front Oncol 11: 727010, 2021.","DOI":"10.3389\/fonc.2021.727010"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Grune J, Yamazoe M, Nahrendorf M. Electroimmunology and cardiac arrhythmia. Nat Rev Cardiol 18: 547-564, 2021.","DOI":"10.1038\/s41569-021-00520-9"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Suzuki S, Satoh T, Yasuoka H, et al. Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J Neuroimmunol 170: 141-149, 2005.","DOI":"10.1016\/j.jneuroim.2005.08.017"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/20\/62_0739-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:29:34Z","timestamp":1715574574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/20\/62_0739-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,15]]},"references-count":45,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0739-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,15]]},"article-number":"0739-22"}}